Role of HCT-comorbidity index, age and disease status at transplantation in predicting survival and non-relapse mortality in patients with myelodysplasia and leukemia undergoing reduced-intensity-conditioning hemopoeitic progenitor cell transplantation

Bone Marrow Transplantation

Volumn 47, Issue 4, 2012, Pages 528-534

  Bokhari, S W ^a   Watson, L ^a   Nagra, S ^b   Cook, M ^b   Byrne, J L ^a   Craddock, C ^b   Russell, N H ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

comorbidity; leukemia; reduced intensityconditioning

Indexed keywords

ALEMTUZUMAB; FLUDARABINE; MELPHALAN;

ADULT; AGE; AGED; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; COMORBIDITY INDEX; CONTROLLED STUDY; DISEASE ACTIVITY; GRAFT REJECTION; HEMATOLOGICAL PARAMETERS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LEUKEMIA; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK BENEFIT ANALYSIS;

ADULT; AGE FACTORS; AGED; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; MYELODYSPLASTIC SYNDROMES; RETROSPECTIVE STUDIES; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84859464311     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2011.138     Document Type: Article

References (24)

1. Farag SS, Archer KJ, Mrozek K, Ruppert AS, Carroll AJ, Vardiman JW et al. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 846. Blood 2006; 108: 63-73. (Pubitemid 43996625)
2. Craig CM, Schiller GJ. Acute myeloid leukemia in the elderly conventional and novel treatment approaches. Blood Rev 2008; 22: 221-234.
3. Dombret H, Raffoux E, Gardin C. Acute myeloid leukemia in the elderly. Semin Oncol 2008; 35: 430-438.
4. Burnett AK, Wheatley K, Goldstone AH, Stevens RF, Hann IM, Rees JF et al. MRC AML12: a comparison of ADE vs MAE and S-DAT vs H-DAT ± retinoic acid for induction and four vs five total courses using chemotherapy or stem cell transplant in consolidation, in 3459 patients under 60 years with AML [abstract]. Blood 2002; 100: 155a.
5. Goldstone AH, Burnett AK, Wheatley K, Smith AG, Hutchinson RM, Clark RE et al. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood 2001; 98: 1302-1311.
6. Niederwieser D, Lange T, Cross M, Basara N, Al-Ali H. Reduced intensity conditioning (RIC) haematopoietic cell transplants in elderly patients with AML. Best Pract Res Clin Haematol 2006; 19: 825-838. (Pubitemid 44418026)
7. Herr AL, Labopin M, Blaise D, Milpied N, Potter M, Michallet M et al. HLA-identical sibling allogeneic peripheral blood stem cell transplantation with reduced intensity conditioning compared to autologous peripheral blood stem cell transplantation for elderly patients with de novo acute myeloid leukemia. Leukemia 2007; 21: 129-135. (Pubitemid 44929343)
8. Ringden O, Labopin M, Ehninger G, Niederwieser D, Olsson R, Basara N et al. Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. J Clin Oncol 2009; 27: 4570-4577.
9. Chakraverty R, Peggs K, Chopra R, Milligan DW, Kottaridis PD, Verfuerth S et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a non-myeloablative conditioning regimen. Blood 2002; 99: 1071-1078. (Pubitemid 34525573)
10. Shore T, Harpel J, Schuster MW, Roboz GJ, Leonard JP, Coleman M et al. A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy. Biol Blood Marrow Transplant 2006; 12: 868-875. (Pubitemid 44070676)
11. Feinstein L, Sandmaier B, Maloney D, McSweeney PA, Maris M, Flowers C et al. Nonmyeloablative hematopoietic cell transplantation. Replacing high-dose cytotoxic therapy by the graft-versus-tumor effect. Ann NY Acad Sci 2001; 938: 328-337; discussion 337-339.
12. Tauro S, Craddock C, Peggs K, Begum G, Mahendra P, Cook G et al. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. J Clin Oncol 2005; 23: 9387-9393.
13. Lim ZY, Ingram W, Brand R, Ho A, Kenyon M, Devereux S et al. Impact of pretransplant comorbidities on alemtuzumab-based reduced-intensity conditioning allogeneic hematopoietic SCT for patients with high-risk myelodysplastic syndrome and AML. Bone Marrow Transplantation 2010; 45: 633-639.
14. Lim Z, Brand R, Martino R, van Biezen A, Finke J, Bacigalupo A et al. hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia. J Clin Oncol 2010; 28: 405-411.
15. Diaconescu R, Flowers CR, Storer B, Sorror ML, Maris MB, Maloney DG et al. Morbidity and mortality with nonmyelo-ablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood 2004; 104: 1550-1558. (Pubitemid 39166537)
16. Xhaard A, Porcher R, Chien JW, de Latour RP, Robin M, Ribaud P et al. Impact of comorbidity indexes on non-relapse mortality. Leukemia 2008; 22: 2062-2069.
17. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912-2919. (Pubitemid 41510773)
18. Sorror ML, Sandmaier BM, Storer BE, Maris MB, Baron F, Maloney DG et al. Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol 2007; 25: 4246-4254. (Pubitemid 47554249)
19. Majhail NS, Brunstein CG, McAvoy S, DeFor TE, Al-Hazzouri A, Setubal D et al. Does the hematopoietic cell transplantation specific comorbidity index predict transplant outcomes? A validation study in a large cohort of umbilical cord blood and matched related donor transplants. Biol Blood Marrow Transplant 2008; 14: 985-992.
20. Guilfoyle R, Demers A, Bredeson C, Richardson E, Rubinger M, Szwajcer D et al. Performance status, but not the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI), predicts mortality at a Canadian transplant center. Bone Marrow Transplant 2009; 43: 133-139.
21. Defor TE, Majhail NS, Weisdorf DJ, Brunstein CG, McAvoy S, Arora M et al. A modified comorbidity index for hematopoietic cell transplantation. Bone Marrow Transplant 2010; 45: 933-938.
22. Aoudjhane M, Labopin M, Gorin NC, Shimoni A, Ruutu T, Kolb HJ et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 2005; 19: 2304-2312. (Pubitemid 41748028)
23. Martino R, Iacobelli S, Brand R, Jansen T, van Biezen A, Finke J et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 2006; 108: 836-846. (Pubitemid 44154615)
24. McClune BL, Weisdorf DJ, Pedersen TL, da Silva GT, Tallman MS, Sierra J et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol 2010; 28: 1878-1887.